Obsidian Therapeutics, Inc. (OBX)

Market Cap	775.87M
Revenue (ttm)	n/a
Net Income	-94.22M
EPS	-31.84
Shares Out	61.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	314,041
Open	12.37
Previous Close	12.48
Day's Range	11.80 - 13.00
52-Week Range	5.70 - 49.97
Beta	3.06
Analysts	Strong Buy
Price Target	39.00 (+210.51%)
Earnings Date	Nov 12, 2026

About OBX

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that le...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 87
• Stock Exchange: Nasdaq
• Ticker Symbol: OBX
• Website: https://obsidiantx.com

Analyst Summary

According to 5 analysts, the average rating for OBX stock is "Strong Buy." The 12-month stock price target is $39.0, which is an increase of 210.51% from the latest price.

Price Target

$39.0

(210.51% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 14, 2026

Data Sources Report a data error